Navigation Links
Inserm announces the recipients of its 2012 prizes
Date:12/4/2012

This press release is available in French.

The 2012 Inserm prizes for medical research will be awarded at a ceremony at the Collge de France on Monday 3 December 2012. This year, the grand prize will be awarded to Philippe Sansonetti in the presence of Marisol Touraine, France's Minister of Social Affairs and Health, Genevive Fioraso, France's Minister of Higher Education and Research, and Professor Andr Syrota, Chairman and CEO of Inserm. The grand prize is awarded each year to honour a member of the scientific research community whose work has contributed to advancing knowledge of human physiology, therapeutics and health in general.

Inserm Grand Prize Philippe Sansonetti

The recipient of the 2012 Grand Prize is Professor Philippe Sansonetti, the director of the Microbial Colonisation and Invasion of Mucosa unit (Inserm Unit 786) at the Institut Pasteur in Paris, in recognition of his research on microbial infection.

Prof. Sansonetti was the first to update the genetic bases in bacteria, particularly in Shigella, which causes dysentery, and which he studied the entire sequence of steps that are required for infection.

Prof. Sansonetti coordinates, along with Pascale Cossart, the Integrative Biology of Emerging Infectious Diseases laboratory of excellence.

International Prize Ingrid Grummt

The recipient of Inserm's International Prize is Professor Ingrid Grummt of the German Cancer Research Centre of Heidelberg in recognition of her epigenetics research on the molecular mechanisms that regulate gene expression.

Honour Prize Jean-Paul Soulillou

The recipient of Inserm's Honour Prize is Professor Jean-Paul Soulillou, who heads Inserm's Lymphocyte Regulation and Tolerance team at the Centre for Transplantation and Immunology Research (Inserm Unit 1064) in Nantes, France, in recognition of his work on transplant tolerance.

Prof. Soulillou is notably behind the development of a "smart" antibody that is widely used to prevent transplant rejection and his research interests include the development of highly effective immunosuppressants.

Research Prizes Sophie Ugolini and Jessica Zucman-Rossi

The Research Prizes are awarded to:

- Sophie Ugolini, an Inserm research director at the Marseille-Luminy Immunology Centre, for her work on the function of natural killer cells (NK cells).

- Jessica Zucman-Rossi, director of the Functional Genomics of Solid Tumours unit in Paris (Inserm Unit 674), for her work on the identification and understanding of the role of gene interactions in human tumours, particularly the Ewing family of tumours.

Innovation Prize Alain de Cesare and Marc Lopez

The Innovation Prizes are awarded to two engineers in recognition of their support in guiding research:

- Alain de Cesare, an Inserm research engineer at the Functional Imaging Laboratory (Inserm Unit 678) in Paris and a designer of medical imaging analysis software.

- Marc Lopez, an Inserm research engineer at the Marseille Oncology Research Centre (Inserm Unit 1068) who identified the cellular adhesion molecules known as nectins.


'/>"/>
Contact: Inserm press office
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related medicine news :

1. EPSRC announces new green engineering projects
2. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Faster Weight Loss than a "No-Diet" Weight Loss Diet
3. Gabrielles Angel Foundation for Cancer Research announces 2 collaborative research grants
4. Feinstein announces submission of new drug application for diagnosing parkinsonian syndromes
5. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
6. Plastic and Reconstructive Surgery Journal announces global expansion initiatives
7. NY-Presbyterian Hospital announces participation in trial for hard-to-treat hypertension
8. Northeasterns Barnett Institute announces formation of leading analytics company, BioAnalytix, LLC
9. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
10. CRF announces late breaking trials and first report investigations to be presented at TCT 2012
11. SfN announces winners of brain awareness video contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: